Hepatitis B Virus-Related Antigens by Beacle, Inc.

Since its establishment in 2002, Beacle, Inc. has engaged in two businesses: developing pharmaceutical-related technologies and manufacturing and selling research-use-only (RUO) reagents. The company's motto is "Developing technologies and products with high originality."

The company develops drug delivery system (DDS) by using the cellular delivery ability of bionanocapsule (BNC), highly sensitive multi-antibody detection (MAD) system using BNC consisting of antibody-binding proteins, and new types of hepatitis B virus (HBV) vaccines using BNC that expresses surface antigens identical to natural HBV. The company also develops RUO reagent products for HBV and immunoassay fields.

Institute of Immunology, Co., Ltd. handles Beacle's unique range of hepatitis B virus (HBV) antigens as in-licensed products. These HBV antigens are classified into three types: particle type, which is made in yeast cells; peptide type, which is made in E. coli; and core type, which is made from genetically modified E. coli.